AGT and ischemic stroke: As a predominate bioactive peptide in RAS, Angiotensin II (AngII) has been suggested to be a significant contributor to the pathophysiology of ischemic stroke [7–9], which, after acting on its receptor (AngII type 1 receptor, AT1R; AngII type 2 receptor, AT2R ), can activate a series of cell signaling pathways, including phosphatidyl inositol (PI) signaling pathways that associated with vasoconstrictor function of Ang II.